Clinical Trial Update: A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating BL-M07D1 in combination with pembrolizumab for unresectable locally advanced or metastatic HER2-overexpressing non-squamous non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Overexpressing Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• BL-M07D1
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non-squamous Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING